Stay updated on Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Sign up to get notified when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.

Latest updates to the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page
- Check5 days agoChange DetectedThe page has been updated to include new information about metastatic melanoma and the involvement of Bristol-Myers Squibb, while significant details regarding the study's dosing and inclusion criteria have been removed.SummaryDifference33%
- Check12 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check56 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check70 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check77 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check92 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
Stay in the know with updates to Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.